Literature DB >> 25596784

ESCMID guideline for the diagnosis and treatment of biofilm infections 2014.

N Høiby1, T Bjarnsholt2, C Moser3, G L Bassi4, T Coenye5, G Donelli6, L Hall-Stoodley7, V Holá8, C Imbert9, K Kirketerp-Møller10, D Lebeaux11, A Oliver12, A J Ullmann13, C Williams14.   

Abstract

Biofilms cause chronic infections in tissues or by developing on the surfaces of medical devices. Biofilm infections persist despite both antibiotic therapy and the innate and adaptive defence mechanisms of the patient. Biofilm infections are characterized by persisting and progressive pathology due primarily to the inflammatory response surrounding the biofilm. For this reason, many biofilm infections may be difficult to diagnose and treat efficiently. It is the purpose of the guideline to bring the current knowledge of biofilm diagnosis and therapy to the attention of clinical microbiologists and infectious disease specialists. Selected hallmark biofilm infections in tissues (e.g. cystic fibrosis with chronic lung infection, patients with chronic wound infections) or associated with devices (e.g. orthopaedic alloplastic devices, endotracheal tubes, intravenous catheters, indwelling urinary catheters, tissue fillers) are the main focus of the guideline, but experience gained from the biofilm infections included in the guideline may inspire similar work in other biofilm infections. The clinical and laboratory parameters for diagnosing biofilm infections are outlined based on the patient's history, signs and symptoms, microscopic findings, culture-based or culture-independent diagnostic techniques and specific immune responses to identify microorganisms known to cause biofilm infections. First, recommendations are given for the collection of appropriate clinical samples, for reliable methods to specifically detect biofilms, for the evaluation of antibody responses to biofilms, for antibiotic susceptibility testing and for improvement of laboratory reports of biofilm findings in the clinical microbiology laboratory. Second, recommendations are given for the prevention and treatment of biofilm infections and for monitoring treatment effectiveness. Finally, suggestions for future research are given to improve diagnosis and treatment of biofilm infections.
Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  biofilm; biofilm diagnosis; biofilm infections; biofilm treatment; biofilm-associated infections; biofilm-based infections; guidelines

Mesh:

Substances:

Year:  2015        PMID: 25596784     DOI: 10.1016/j.cmi.2014.10.024

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  175 in total

Review 1.  [Orthopaedic implant-associated infections: Update of antimicrobial therapy].

Authors:  W Zimmerli
Journal:  Orthopade       Date:  2015-12       Impact factor: 1.087

Review 2.  Host Peptidic Hormones Affecting Bacterial Biofilm Formation and Virulence.

Authors:  Olivier Lesouhaitier; Thomas Clamens; Thibaut Rosay; Florie Desriac; Mélissande Louis; Sophie Rodrigues; Andrei Gannesen; Vladimir K Plakunov; Emeline Bouffartigues; Ali Tahrioui; Alexis Bazire; Alain Dufour; Pierre Cornelis; Sylvie Chevalier; Marc G J Feuilloley
Journal:  J Innate Immun       Date:  2018-11-05       Impact factor: 7.349

Review 3.  Sensing the unreachable: challenges and opportunities in biofilm detection.

Authors:  Yikang Xu; Yousr Dhaouadi; Paul Stoodley; Dacheng Ren
Journal:  Curr Opin Biotechnol       Date:  2019-11-22       Impact factor: 9.740

4.  Biofilm formation - what we can learn from recent developments.

Authors:  T Bjarnsholt; K Buhlin; Y F Dufrêne; M Gomelsky; A Moroni; M Ramstedt; K P Rumbaugh; T Schulte; L Sun; B Åkerlund; U Römling
Journal:  J Intern Med       Date:  2018-07-09       Impact factor: 8.989

5.  In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin.

Authors:  Ebru Evren; Erkan Yurtcu
Journal:  Folia Microbiol (Praha)       Date:  2015-05-04       Impact factor: 2.099

6.  Antimicrobial Blue Light Inactivation of Gram-Negative Pathogens in Biofilms: In Vitro and In Vivo Studies.

Authors:  Yucheng Wang; Ximing Wu; Jia Chen; Rehab Amin; Min Lu; Brijesh Bhayana; Jie Zhao; Clinton K Murray; Michael R Hamblin; David C Hooper; Tianhong Dai
Journal:  J Infect Dis       Date:  2016-02-17       Impact factor: 5.226

7.  Microscopy visualisation confirms multi-species biofilms are ubiquitous in diabetic foot ulcers.

Authors:  Khalid Johani; Matthew Malone; Slade Jensen; Iain Gosbell; Hugh Dickson; Honhua Hu; Karen Vickery
Journal:  Int Wound J       Date:  2017-06-23       Impact factor: 3.315

8.  New in vitro model to study the effect of human simulated antibiotic concentrations on bacterial biofilms.

Authors:  Janus A J Haagensen; Davide Verotta; Liusheng Huang; Alfred Spormann; Katherine Yang
Journal:  Antimicrob Agents Chemother       Date:  2015-04-27       Impact factor: 5.191

9.  Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction.

Authors:  Matteo Rinaldi; Pier Giorgio Cojutti; Eleonora Zamparini; Sara Tedeschi; Nicolò Rossi; Matteo Conti; Maddalena Giannella; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

Review 10.  Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections.

Authors:  Werner Zimmerli; Parham Sendi
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.